IIT People Search

Francesco Rinaldi

Ph.D Fellow
PhD Student Fellow
Computational and Chemical Biology
Research center
About

Mr. Francesco Rinaldi studied Pharmacy at Alma Mater Studiorum - University of Bologna. From September 2016 to March 2017 he performed the Pharmacy Internship at the Maggiore Hospital in Bologna (AUSL Bologna). In 2017 Mr. Rinaldi moved to the Italian Institute of Technology in Genoa for a 3 months inthernship period working on the expression and the purification of proteins of pharmaceutical interest. Then, he spent 6 months, at ETH Zurich in Prof. Dario Neri Biomacromolecules group, to perform his Master Thesis, focused on the development of new monoclonal antibodies. His master thesis contributed to a paper, published on Leukemia Research in June 2019, entitled "Development of a new monoclonal antibody against CD123 for the treatment of Acute Myeloid Lekaemia".

In March 2018 he graduated in Pharmacy with a final mark of 110/110 cum laude. Later in June he passed the State Examination for Pharmacists with the overall mark of 292/350. He is enrolled as a member of the Bologna Pharmacist order.

During 2018 he followed the Summer School in Metodology of Clinical Research and the training course "Education of the Community Pharmacist" organized by Prof. Maurizio Cini, at University of Bologna. 

Mr. Rinaldi has been External Collaborator in Prof. Andrea Cavalli Computational and Chemical Biology group from January 2019 to October 2019, working on the expression and purification of a monomeric form of RAD51,for the validation of new chemical compounds and peptides as protein inhibitors.

Since November 2019 is a PhD Fellow in Prof. Andrea Cavalli group grading first after the selection process at the Alma Mater Studiorum - University of Bologna and working on a project entitled "Innovative approaches to overcome drug-resistance in cancer".

In November 2020 Mr. Francesco Rinaldi has been awarded of a triennal FIRC-AIRC fellowship for a project entitled "Unveiling the molecular mechanism of BRCA2-RAD51 interaction to tackle cancer onset"

Education

Title: Pharm. D.
Institute: Alma Mater Studiorum - University of Bologna
Location: Bologna
Country: Italy
From: 2012 To: 2018

Title: Ph.D.
Institute: Istituto Italiano di Tecnologia and Alma Mater Studiorum - University of Bologna
Location: Genoa
Country: Italy
From: 2019 To: 2023

Certificate

Title: Pharmacists State Examination
Description: null
Date: 31-07-2018

Experience External

Title: Master Thesis Student
Institute: ETH Zurich
Location: Zurich
Country: Switzerland
From: 2017 To: 2018

All Publications
2023
Poppi L., Myers S.H., Previtali V., Rinaldi F., Farabegol F., Di Stefano G., Walsh N., Roberti M., Cavalli A.
A RAD51/BRCA2 small molecule inhibitor enhances the antineoplastic effect of the PARPi talazoparib in pancreatic cancer
EACR
Poster Conference
2023
Rinaldi F., Bernetti M., Bresciani V., Girotto S., Cavalli A.
Dissecting the BRCA2 - RAD51 interaction by integrating computational and experimental biophysics
EMBO Practical Course Integrative modelling of protein interactions
Poster Conference
2023
Balboni B., Rinaldi F., Previtali V., Ciamarone A., Girotto S., Cavalli A.
Novel Insights into RAD52’s Structure, Function, and Druggability for Synthetic Lethality and Innovative Anticancer Therapies
Cancers, vol. 15, (no. 6)
Review Journal
2022
Myers S. H., Previtali V., Poppi L., Rinaldi F., Schipani F., Ortega J. O., De Franco F., Veronesi M., Pellicciari R., Roberti M., Girotto S., Di Stefano G., Cavalli A.
Identification and subsequent development of RAD51 inhibitors as potential tools in exploring BRCA2-PARP mediated synthetic lethality
ACS Spring 2022 meeting
Poster Conference
2022
Previtali V., Myers S. H., Bagnolini G., Poppi L., Rinaldi F., Schipani F., Ortega J. A., De Franco F., Pellicciari R., Girotto S., Oliviero G., Walsh N., Valenti G., Tirelli N., Di Stefano G., Roberti M., Cavalli A.
Insights into the activity of ARN24089, a new RAD51-BRCA2 disruptor that inhibits homologous recombination and achieves synthetic lethality in pancreatic cancer
ACS Spring 2022 meeting
Poster Conference
Scientific Talks
2023
Rinaldi F.
Dissecting the BRCA2 - RAD51 interaction by integrating computational and experimental biophysics
Human Technopole
Institute
2023
Rinaldi F., Bernetti M., Bresciani V., Girotto S., Cavalli A.
Elucidating the BRCA2 - RAD51 interaction by integrating computational and experimental biophysics
Convegno Nazionale della Società Chimica Italiana - Divisione di Chimica dei Sistemi Biologici
Conference
2023
Rinaldi F., Girotto S., Cavalli A.
Elucidating the BRCA2-RAD51 interaction through an integrated structural biophysics approach
Italian Cristallography Association - 4th Meeting of the Biological Macromolecules Section
Conference
2023
Rinaldi F.
Integrative Structural Modelling of the RAD51-BRCA2 interaction
The impact of computational methods and HPC on Life Sciences
Workshop/Symposium
Oral presentations
2022
Previtali V., Myers S. H., Bagnolini G., Poppi L., Rinaldi F., Schipani F., Ortega J. A., De Franco F., Pellicciari R., Girotto S., Oliviero G., Walsh N., Valenti G., Tirelli N., Di Stefano G., Roberti M., Cavalli A.
Insights into the activity of ARN24089, a new RAD51-BRCA2 disruptor that inhibits homologous recombination and achieves synthetic lethality in pancreatic cancer
ACS Spring 2022 meeting
Conference
Awards and Achievements
2020
Rinaldi F.
Triennal FIRC-AIRC fellowship "Ignazia Larussa" ID 25239
2018
Rinaldi F.
Scholarship for students developing an internship in A.Y. 2016
2017
Rinaldi F.
Scholarship for the development of the Master Thesis in a foreing laboratory